161 related articles for article (PubMed ID: 38503660)
1. High throughput AS LNA qPCR method for the detection of a specific mutation in poliovirus vaccine strains.
Opmeer L; Gazzoli I; Ballmann M; Willemsen M; Voshol GP; Grudniewska-Lawton M; Havenga M; Yallop C; Hamidi A; Gillissen G; Bakker WAM
Vaccine; 2024 Apr; 42(9):2475-2484. PubMed ID: 38503660
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the genetic stability of Sabin strains and the consistency of inactivated poliomyelitis vaccine made from Sabin strains using direct deep-sequencing.
Deng Y; Cai W; Li J; Li Y; Yang X; Ma Y; Yao Y; Yang L; Shi L; Sun M
Vaccine; 2019 Jan; 37(1):130-136. PubMed ID: 30467062
[TBL] [Abstract][Full Text] [Related]
3. Differences in Antigenic Structure of Inactivated Polio Vaccines Made From Sabin Live-Attenuated and Wild-Type Poliovirus Strains: Impact on Vaccine Potency Assays.
Crawt L; Atkinson E; Tedcastle A; Pegg E; ; Minor P; Cooper G; Rigsby P; Martin J
J Infect Dis; 2020 Feb; 221(4):544-552. PubMed ID: 30788503
[TBL] [Abstract][Full Text] [Related]
4. VaxArray immunoassay for the multiplexed quantification of poliovirus D-antigen.
Dawson ED; Taylor AW; Johnson JE; Hu T; McCormick C; Thomas KN; Gao RY; Wahid R; Mahmood K; Rowlen KL
J Immunol Methods; 2022 May; 504():113259. PubMed ID: 35314144
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity of three sequential schedules with Sabin inactivated poliovirus vaccine and bivalent oral poliovirus vaccine in Zhejiang, China: an open-label, randomised, controlled trial.
He H; Wang Y; Deng X; Yue C; Tang X; Li Y; Liu Y; Yin Z; Zhang G; Chen Z; Xie S; Wen N; An Z; Chen Z; Wang H
Lancet Infect Dis; 2020 Sep; 20(9):1071-1079. PubMed ID: 32442523
[TBL] [Abstract][Full Text] [Related]
6. Sporadic isolation of sabin-like polioviruses and high-level detection of non-polio enteroviruses during sewage surveillance in seven Italian cities, after several years of inactivated poliovirus vaccination.
Battistone A; Buttinelli G; Fiore S; Amato C; Bonomo P; Patti AM; Vulcano A; Barbi M; Binda S; Pellegrinelli L; Tanzi ML; Affanni P; Castiglia P; Germinario C; Mercurio P; Cicala A; Triassi M; Pennino F; Fiore L
Appl Environ Microbiol; 2014 Aug; 80(15):4491-501. PubMed ID: 24814793
[TBL] [Abstract][Full Text] [Related]
7. Cross-neutralization Capacity of Immune Serum from Different Dosage of Sabin Inactivated Poliovirus Vaccine Immunization against Multiple Individual Polioviruses.
Chu K; Han W; Jiang D; Jiang Z; Zhu T; Xu W; Hu Y; Zeng G
Expert Rev Vaccines; 2021 Jun; 20(6):761-767. PubMed ID: 33861679
[No Abstract] [Full Text] [Related]
8. Rapid and accurate identification of poliovirus strains used for vaccine production.
Nijst OE; Mouthaan JJ; Mekkes DR; Jusic E; van der Avoort HG; Metz B
J Virol Methods; 2013 Apr; 189(1):189-95. PubMed ID: 23434540
[TBL] [Abstract][Full Text] [Related]
9. Correlation between vaccine coverage against polio and circulation and genetic evolution of the poliovirus strains isolated in Romania in the framework of the global polio eradication strategy.
Băicuş A; Persu A; Popescu M; Penciu A; Stavri S; Soare A; Grecu N; Szmal C; Oprişan G
Roum Arch Microbiol Immunol; 2009; 68(3):145-50. PubMed ID: 20361534
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of immunogenicity and protective properties of inactivated poliovirus vaccines: a new surrogate method for predicting vaccine efficacy.
Dragunsky EM; Ivanov AP; Wells VR; Ivshina AV; Rezapkin GV; Abe S; Potapova SG; Enterline JC; Hashizume S; Chumakov KM
J Infect Dis; 2004 Oct; 190(8):1404-12. PubMed ID: 15378432
[TBL] [Abstract][Full Text] [Related]
11. Safety and immunogenicity of a primary series of Sabin-IPV with and without aluminum hydroxide in infants.
Verdijk P; Rots NY; van Oijen MG; Weldon WC; Oberste MS; Okayasu H; Sutter RW; Bakker WA
Vaccine; 2014 Sep; 32(39):4938-44. PubMed ID: 25043278
[TBL] [Abstract][Full Text] [Related]
12. Sabin Vaccine Reversion in the Field: a Comprehensive Analysis of Sabin-Like Poliovirus Isolates in Nigeria.
Famulare M; Chang S; Iber J; Zhao K; Adeniji JA; Bukbuk D; Baba M; Behrend M; Burns CC; Oberste MS
J Virol; 2016 Jan; 90(1):317-31. PubMed ID: 26468545
[TBL] [Abstract][Full Text] [Related]
13. Development of Thermostable Lyophilized Sabin Inactivated Poliovirus Vaccine.
Shin WJ; Hara D; Gbormittah F; Chang H; Chang BS; Jung JU
mBio; 2018 Nov; 9(6):. PubMed ID: 30482835
[TBL] [Abstract][Full Text] [Related]
14. Multiplex PCR-based titration (MPBT) assay for determination of infectious titers of the three Sabin strains of live poliovirus vaccine.
Manukyan H; Rodionova E; Zagorodnyaya T; Lin TL; Chumakov K; Laassri M
Virol J; 2019 Oct; 16(1):122. PubMed ID: 31660997
[TBL] [Abstract][Full Text] [Related]
15. Isolation of sabin-like polioviruses from wastewater in a country using inactivated polio vaccine.
Zurbriggen S; Tobler K; Abril C; Diedrich S; Ackermann M; Pallansch MA; Metzler A
Appl Environ Microbiol; 2008 Sep; 74(18):5608-14. PubMed ID: 18641161
[TBL] [Abstract][Full Text] [Related]
16. sIPV process development for costs reduction.
Thomassen YE; Bakker WA
Vaccine; 2015 Aug; 33(35):4307-12. PubMed ID: 25858858
[TBL] [Abstract][Full Text] [Related]
17. Safety and immunogenicity of inactivated poliovirus vaccine made from Sabin strains: A phase II, randomized, dose-finding trial.
Chu K; Ying Z; Wang L; Hu Y; Xia J; Chen L; Wang J; Li C; Zhang Q; Gao Q; Hu Y
Vaccine; 2018 Oct; 36(45):6782-6789. PubMed ID: 30249424
[TBL] [Abstract][Full Text] [Related]
18. An inactivated poliovirus vaccine using Sabin strains produced on the serum-free PER.C6® cell culture platform is immunogenic and safe in a non-human primate model.
Bockstal V; Tiemessen MM; Achterberg R; Van Wordragen C; Knaapen AM; Serroyen J; Marissen WE; Schuitemaker H; Zahn R
Vaccine; 2018 Nov; 36(46):6979-6987. PubMed ID: 30314910
[TBL] [Abstract][Full Text] [Related]
19. Analysis of the dose-sparing effect of adjuvanted Sabin-inactivated poliovirus vaccine (sIPV).
Li Z; Ding W; Guo Q; Liu Z; Zhu Z; Song S; Li W; Liao G
Hum Vaccin Immunother; 2018; 14(8):1987-1994. PubMed ID: 29601259
[TBL] [Abstract][Full Text] [Related]
20. Safety and immunogenicity of experimental stand-alone trivalent, inactivated Sabin-strain polio vaccine formulations in healthy infants: A randomized, observer-blind, controlled phase 1/2 trial.
Cramer JP; Jimeno J; Han HH; Lin S; Hartmann K; Borkowski A; Sáez-Llorens X
Vaccine; 2020 Jul; 38(33):5313-5323. PubMed ID: 32563609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
